Astrazeneca loses more than 3% on the London Stock Exchange after the pharmaceutical company said a study comparing its best-selling cholesterol drug, Crestor, with Pfizer's Lipitor, did not reveal a significant advantage. favor of the former. The risk is that Crestor sales could be damaged by the arrival of Lipitor clone drugs on the market, given that at the end of 2011 Pfizer will lose the exclusivity of the license.
(SF)
02/09/2011 
